Innovation Pharmaceuticals Inc (IPIX)

[noretreat]

We don't know any of the actual numbers yet, and a more muted response from the market is to be expected until more results are available. These dosages seem to have worked at least as well as the dosages in the p2a, and they are within the (rather wide) range of statistical parity with Daptomycin.

All good results...but many questions remain. As soon as there is some actual data, I can give you the probabilities of success in the larger p3 trial, where the ranges tighten.